FR15C0017I1 - - Google Patents

Info

Publication number
FR15C0017I1
FR15C0017I1 FR15C0017C FR15C0017I1 FR 15C0017 I1 FR15C0017 I1 FR 15C0017I1 FR 15C0017 C FR15C0017 C FR 15C0017C FR 15C0017 I1 FR15C0017 I1 FR 15C0017I1
Authority
FR
France
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
Other languages
French (fr)
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=34956036&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=FR15C0017(I1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed filed Critical
Publication of FR15C0017I1 publication Critical patent/FR15C0017I1/fr
Application granted granted Critical
Publication of FR15C0017I2 publication Critical patent/FR15C0017I2/fr
Active legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/138—Aryloxyalkylamines, e.g. propranolol, tamoxifen, phenoxybenzamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/167—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/196—Carboxylic acids, e.g. valproic acid having an amino group the amino group being directly attached to a ring, e.g. anthranilic acid, mefenamic acid, diclofenac, chlorambucil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/275—Nitriles; Isonitriles
    • A61K31/277—Nitriles; Isonitriles having a ring, e.g. verapamil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/407—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with other heterocyclic ring systems, e.g. ketorolac, physostigmine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/439—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom the ring forming part of a bridged ring system, e.g. quinuclidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/46—8-Azabicyclo [3.2.1] octane; Derivatives thereof, e.g. atropine, cocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/655—Azo (—N=N—), diazo (=N2), azoxy (>N—O—N< or N(=O)—N<), azido (—N3) or diazoamino (—N=N—N<) compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/0075—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a dry powder inhaler [DPI], e.g. comprising micronized drug mixed with lactose carrier particles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pulmonology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Emergency Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Otolaryngology (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Rheumatology (AREA)
  • Immunology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medical Preparation Storing Or Oral Administration Devices (AREA)
  • Wrappers (AREA)
FR15C0017C 2004-05-31 2015-02-24 Combinaison, produit, kit de parties, conditionnement comprenant des agents muscariniques et des agonistes beta-adrenergiques et procede de traitement les utilisant Active FR15C0017I2 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
ES200401312A ES2257152B1 (es) 2004-05-31 2004-05-31 Combinaciones que comprenden agentes antimuscarinicos y agonistas beta-adrenergicos.
FR0505473A FR2870744B1 (fr) 2004-05-31 2005-05-31 Combinaison, produit, kit de parties, conditionnement comprenant des agents muscariniques et des agonistes beta-adrenergiques et procede de traitement les utilisant

Publications (2)

Publication Number Publication Date
FR15C0017I1 true FR15C0017I1 (enrdf_load_stackoverflow) 2015-03-04
FR15C0017I2 FR15C0017I2 (fr) 2015-11-13

Family

ID=34956036

Family Applications (2)

Application Number Title Priority Date Filing Date
FR0505473A Expired - Lifetime FR2870744B1 (fr) 2004-05-31 2005-05-31 Combinaison, produit, kit de parties, conditionnement comprenant des agents muscariniques et des agonistes beta-adrenergiques et procede de traitement les utilisant
FR15C0017C Active FR15C0017I2 (fr) 2004-05-31 2015-02-24 Combinaison, produit, kit de parties, conditionnement comprenant des agents muscariniques et des agonistes beta-adrenergiques et procede de traitement les utilisant

Family Applications Before (1)

Application Number Title Priority Date Filing Date
FR0505473A Expired - Lifetime FR2870744B1 (fr) 2004-05-31 2005-05-31 Combinaison, produit, kit de parties, conditionnement comprenant des agents muscariniques et des agonistes beta-adrenergiques et procede de traitement les utilisant

Country Status (45)

Country Link
US (41) US20050267078A1 (enrdf_load_stackoverflow)
EP (14) EP2002845A3 (enrdf_load_stackoverflow)
JP (8) JP5032984B2 (enrdf_load_stackoverflow)
KR (3) KR101256417B1 (enrdf_load_stackoverflow)
CN (8) CN1960762A (enrdf_load_stackoverflow)
AR (1) AR049066A1 (enrdf_load_stackoverflow)
AT (3) ATE424847T1 (enrdf_load_stackoverflow)
AU (3) AU2005247107B2 (enrdf_load_stackoverflow)
BE (1) BE1016608A5 (enrdf_load_stackoverflow)
BR (6) BRPI0511656A (enrdf_load_stackoverflow)
CA (3) CA2569077C (enrdf_load_stackoverflow)
CH (1) CH696962A5 (enrdf_load_stackoverflow)
CL (1) CL2011000607A1 (enrdf_load_stackoverflow)
CY (7) CY1108885T1 (enrdf_load_stackoverflow)
DE (3) DE602005013220D1 (enrdf_load_stackoverflow)
DK (5) DK1763368T4 (enrdf_load_stackoverflow)
EC (6) ECSP067036A (enrdf_load_stackoverflow)
ES (7) ES2257152B1 (enrdf_load_stackoverflow)
FR (2) FR2870744B1 (enrdf_load_stackoverflow)
GB (1) GB2419819B (enrdf_load_stackoverflow)
GR (1) GR1006045B (enrdf_load_stackoverflow)
HR (4) HRP20090107T3 (enrdf_load_stackoverflow)
HU (2) HUP0600139A3 (enrdf_load_stackoverflow)
IL (3) IL179684A (enrdf_load_stackoverflow)
IT (1) ITMI20051021A1 (enrdf_load_stackoverflow)
LT (1) LTC1763368I2 (enrdf_load_stackoverflow)
LU (1) LU91214B1 (enrdf_load_stackoverflow)
MC (1) MC200083A1 (enrdf_load_stackoverflow)
ME (4) ME02779B (enrdf_load_stackoverflow)
MX (3) MXPA06013847A (enrdf_load_stackoverflow)
MY (1) MY142095A (enrdf_load_stackoverflow)
NL (2) NL1029151C2 (enrdf_load_stackoverflow)
NO (7) NO338621B1 (enrdf_load_stackoverflow)
NZ (3) NZ551668A (enrdf_load_stackoverflow)
PE (3) PE20081650A1 (enrdf_load_stackoverflow)
PL (6) PL2292267T3 (enrdf_load_stackoverflow)
PT (4) PT1891973E (enrdf_load_stackoverflow)
RS (4) RS51386B (enrdf_load_stackoverflow)
RU (4) RU2404771C3 (enrdf_load_stackoverflow)
SI (5) SI1891973T1 (enrdf_load_stackoverflow)
TW (1) TWI404530B (enrdf_load_stackoverflow)
UA (6) UA89185C2 (enrdf_load_stackoverflow)
UY (1) UY28933A1 (enrdf_load_stackoverflow)
WO (3) WO2005115462A1 (enrdf_load_stackoverflow)
ZA (6) ZA200600261B (enrdf_load_stackoverflow)

Families Citing this family (56)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR100471016B1 (ko) * 1996-08-07 2005-07-12 스미또모 가가꾸 가부시키가이샤 살충성에어로졸조성물및이를제조하기위한살충조성물
ES2165768B1 (es) 1999-07-14 2003-04-01 Almirall Prodesfarma Sa Nuevos derivados de quinuclidina y composiciones farmaceuticas que los contienen.
US20050026948A1 (en) * 2003-07-29 2005-02-03 Boehringer Ingelheim International Gmbh Medicaments for inhalation comprising an anticholinergic and a betamimetic
KR20060052912A (ko) * 2003-07-29 2006-05-19 베링거 인겔하임 인터내셔날 게엠베하 항콜린제와 스테로이드의 배합물 및 흡입으로 호흡기장애를 치료하기 위한 이의 용도
ES2257152B1 (es) * 2004-05-31 2007-07-01 Laboratorios Almirall S.A. Combinaciones que comprenden agentes antimuscarinicos y agonistas beta-adrenergicos.
SI1891974T1 (sl) * 2004-05-31 2010-11-30 Almirall Sa Kombinacije ki obsegajo antimuskarinska sredstvain PDE innhibitorje
US20100150884A1 (en) * 2005-02-10 2010-06-17 Oncolys Biopharma Inc. Anticancer Agent to Be Combined with Telomelysin
HRP20090498T1 (hr) * 2005-12-21 2009-10-31 Meda Pharma Gmbh & Co. Kg Kombinacija r,r-glikopirolata, roliprama i budesonida za liječenje upalnih oboljenja
US20090264388A1 (en) * 2006-02-22 2009-10-22 Valorisation Recherche Hscm, Limited Partnership Compounds and Methods of Treating Disorders Associated With Activation of Metachromatic Cells
US8007790B2 (en) * 2006-04-03 2011-08-30 Stowers Institute For Medical Research Methods for treating polycystic kidney disease (PKD) or other cyst forming diseases
TWI436761B (zh) * 2006-06-19 2014-05-11 Otsuka Pharma Co Ltd 使用噻唑衍生物之方法
EP2040707B1 (en) * 2006-07-05 2011-11-30 Nycomed GmbH Combination of atorvastatin with a phosphodiesterase 4 inhibitor for the treatment of inflammatory pulmonary diseases
KR20090030347A (ko) 2006-07-19 2009-03-24 아스트라제네카 아베 신규 트리시클릭 스피로피페리딘 화합물, 이들의 합성 및 이들의 케모킨 수용체 활성의 조절제로서의 용도
ES2298049B1 (es) 2006-07-21 2009-10-20 Laboratorios Almirall S.A. Procedimiento para fabricar bromuro de 3(r)-(2-hidroxi-2,2-ditien-2-ilacetoxi)-1-(3-fenoxipropil)-1-azoniabiciclo (2.2.2) octano.
CN101616670A (zh) * 2007-02-21 2009-12-30 奥米罗有限公司 新方法
CA2608561A1 (en) * 2007-10-29 2009-04-29 Carl Paluszkiewicz Motorcycle wind deflector accessory support
EP2080523A1 (en) * 2008-01-15 2009-07-22 CHIESI FARMACEUTICI S.p.A. Compositions comprising an antimuscarinic and a long-acting beta-agonist
EP2080508A1 (en) * 2008-01-15 2009-07-22 CHIESI FARMACEUTICI S.p.A. Dry powder formulation comprising an anticholinergic drug
EP2100599A1 (en) * 2008-03-13 2009-09-16 Laboratorios Almirall, S.A. Inhalation composition containing aclidinium for treatment of asthma and chronic obstructive pulmonary disease
EP2100598A1 (en) * 2008-03-13 2009-09-16 Laboratorios Almirall, S.A. Inhalation composition containing aclidinium for treatment of asthma and chronic obstructive pulmonary disease
NZ587591A (en) * 2008-03-14 2012-10-26 Otsuka Pharma Co Ltd Diarylthiazole derivatives such as tetomilast as mmp-2 and/or mmp-9 inhibitors
DK2297106T3 (da) 2008-05-27 2014-10-06 Astrazeneca Ab Phenoxypyridinylamidderivater og deres anvendelse til behandling af pde4-medierede sygdomstilstande
GB0814729D0 (en) * 2008-08-12 2008-09-17 Argenta Discovery Ltd New combination
EP2156847A1 (en) * 2008-08-19 2010-02-24 Sanofi-Aventis New combination of active ingredients containing an alpha1-antagonist and a PDE 4 inhibitor.
ES2739352T3 (es) 2009-02-26 2020-01-30 Glaxo Group Ltd Formulaciones farmacéuticas que comprenden 4-{(1R)-2-[(6-{2-[(2,6-diclorobencil)oxi]etoxi}hexil)amino]-1-hidroxietil}-2-(hidroximetil)fenol
PL3061821T3 (pl) 2009-07-22 2020-01-31 PureTech Health LLC Kompozycje do leczenia zaburzeń łagodzonych przez aktywację receptora muskarynowego
US10265311B2 (en) 2009-07-22 2019-04-23 PureTech Health LLC Methods and compositions for treatment of disorders ameliorated by muscarinic receptor activation
GB0921075D0 (en) 2009-12-01 2010-01-13 Glaxo Group Ltd Novel combination of the therapeutic agents
EA024922B1 (ru) 2010-08-03 2016-11-30 КЬЕЗИ ФАРМАЧЕУТИЧИ С.п.А. Сухой порошковый препарат, содержащий ингибитор фосфодиэстеразы
EP2510928A1 (en) 2011-04-15 2012-10-17 Almirall, S.A. Aclidinium for use in improving the quality of sleep in respiratory patients
ES2552538T3 (es) 2011-06-10 2015-11-30 Chiesi Farmaceutici S.P.A. Compuestos que tienen una actividad antagonista de un receptor muscarínico y agonista de un receptor beta-2 adrenérgico
WO2012168349A1 (en) 2011-06-10 2012-12-13 Chiesi Farmaceutici S.P.A. Compounds having muscarinic receptor antagonist and beta2 adrenergic receptor agonist activity
HRP20181550T1 (hr) * 2012-01-25 2018-11-30 Chiesi Farmaceutici S.P.A. Formulacija suhog praška koja sadrži kortikosteroid i beta-adrenergik za davanje inhalacijom
RU2666963C2 (ru) 2012-04-13 2018-09-13 Глаксосмитклайн Интеллекчуал Проперти Дивелопмент Лимитед Агрегированные частицы
WO2014014698A2 (en) * 2012-07-16 2014-01-23 Barry University Inc. Bitopic muscarinic agonists and antagonists and methods of synthesis and use thereof
MA38147B1 (fr) 2012-12-06 2018-09-28 Chiesi Farm Spa Composés ayant une activité antagoniste du récepteur muscarinique et agoniste du récepteur bêta2 adrénergique
KR102156441B1 (ko) 2012-12-06 2020-09-17 키에시 파르마슈티시 엣스. 피. 에이. 무스카린성 수용체 길항제 및 베타2 아드레날린성 수용체 효능제 활성을 가지는 화합물
GB201222679D0 (en) 2012-12-17 2013-01-30 Glaxo Group Ltd Pharmaceutical combination products
EP2968312B1 (en) * 2013-03-15 2018-01-31 Verona Pharma PLC Drug combination
US10711334B2 (en) * 2013-10-09 2020-07-14 Mirus Llc Metal alloy for medical devices
CN105916940B (zh) 2013-11-15 2019-04-09 罗地亚经营管理公司 用于金属涂层的聚酰胺组合物以及涂覆有其的金属部件
CN106029051A (zh) * 2014-01-10 2016-10-12 尊严科学有限公司 包含15-hepe的药物组合物以及使用其治疗哮喘和肺病症的方法
TWI703138B (zh) 2015-02-12 2020-09-01 義大利商吉斯藥品公司 具有蕈毒鹼受體拮抗劑及β２腎上腺素受體促效劑活性之化合物
AR104828A1 (es) 2015-06-01 2017-08-16 Chiesi Farm Spa COMPUESTOS CON ACTIVIDAD ANTAGONISTA DE LOS RECEPTORES MUSCARÍNICOS Y ACTIVIDAD AGONISTA DEL RECEPTOR b2 ADRENÉRGICO
EP3383867B1 (en) 2015-12-03 2021-04-14 Chiesi Farmaceutici S.p.A. Compounds having muscarinic receptor antagonist and beta2 adrenergic receptor agonist activity
US10835514B2 (en) * 2016-01-08 2020-11-17 Theron Pharmaceuticals, Inc. Dry powder inhaler compositions of 7-azoniabicyclo[2.2.1]heptane derivatives
EP3484879B1 (en) 2016-07-13 2020-12-30 Chiesi Farmaceutici S.p.A. Hydroxyquinolinone compounds having muscarinic receptor antagonist and beta2 adrenergic receptor agonist activity
US11065235B2 (en) 2017-05-19 2021-07-20 Council Of Scientific & Industrial Research Substituted methanopyrido [2, 1-a] isoindolones as mAChR modulators for treating various associated pathophysiological conditions and process for preparation thereof
WO2019147824A1 (en) 2018-01-26 2019-08-01 Progenity, Inc. Treatment of a disease of the gastrointestinal tract with a pde4 inhibitor
AU2019346626B2 (en) 2018-09-28 2022-06-02 Karuna Therapeutics, Inc. Compositions and methods for treating disorders ameliorated by muscarinic receptor activation
US20220249814A1 (en) 2018-11-19 2022-08-11 Progenity, Inc. Methods and devices for treating a disease with biotherapeutics
US11707610B2 (en) 2019-12-13 2023-07-25 Biora Therapeutics, Inc. Ingestible device for delivery of therapeutic agent to the gastrointestinal tract
IT202000006442A1 (it) * 2020-03-27 2021-09-27 Genetic S P A Budesonide 21-phosphate salts and pharmaceutical compositions containing the same
US20210315851A1 (en) 2020-04-03 2021-10-14 Afimmune Limited Compositions comprising 15-hepe and methods of treating or preventing hematologic disorders, and/or related diseases
US11504332B2 (en) * 2021-03-23 2022-11-22 Vk Research Associates Inc. Phosphodiesterase-4 inhibitor combinations, methods of making, and methods of use thereof
KR20240109240A (ko) * 2021-09-23 2024-07-10 큐라센 테라퓨틱스, 인코포레이티드 베타 아드레날린 작용제 및 이의 사용 방법

Family Cites Families (119)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1219606A (en) * 1968-07-15 1971-01-20 Rech S Et D Applic Scient Soge Quinuclidinol derivatives and preparation thereof
FR2414044A1 (fr) * 1978-01-10 1979-08-03 Pharmindustrie Nouveaux derives d'aza-1 bicyclo(2,2,2) octane, utilisables comme medicaments
IT7920688U1 (it) 1979-02-05 1980-08-05 Chiesi Paolo Inalatore per sostanze medicamentose pulverulente, con combinata funzione di dosatore
CY1492A (en) 1981-07-08 1990-02-16 Draco Ab Powder inhalator
FR2539135B1 (fr) * 1983-01-11 1986-02-28 Essilor Int Hydrogels de polyurethane et procede de fabrication
US4570630A (en) 1983-08-03 1986-02-18 Miles Laboratories, Inc. Medicament inhalation device
GB8334494D0 (en) * 1983-12-24 1984-02-01 Tanabe Seiyaku Co Carbostyril derivatives
FI69963C (fi) 1984-10-04 1986-09-12 Orion Yhtymae Oy Doseringsanordning
US4675326A (en) * 1985-05-08 1987-06-23 Gabriel Amitai Bisquaternary antidotes
US4843074A (en) * 1988-05-17 1989-06-27 Marion Laboratories, Inc. 1-azabicyclo[2.2.2]octan-3-yl 2-aryl-3-azacyclo-2-hydroxypropionates and their quaternary salts
DE3927170A1 (de) * 1989-08-17 1991-02-21 Boehringer Ingelheim Kg Inhalator
US5290815A (en) * 1989-09-07 1994-03-01 Glaxo Group Limited Treatment of inflammation and allergy
US5610163A (en) * 1989-09-16 1997-03-11 Boehringer Ingelheim Gmbh Esters of thienyl carboxylic acids and amino alcohols and their quaternization products
IT1237118B (it) 1989-10-27 1993-05-18 Miat Spa Inalatore multidose per farmaci in polvere.
US5201308A (en) * 1990-02-14 1993-04-13 Newhouse Michael T Powder inhaler
GB9004781D0 (en) 1990-03-02 1990-04-25 Glaxo Group Ltd Device
SG45171A1 (en) 1990-03-21 1998-01-16 Boehringer Ingelheim Int Atomising devices and methods
GB9015522D0 (en) 1990-07-13 1990-08-29 Braithwaite Philip W Inhaler
WO1992003175A1 (en) 1990-08-11 1992-03-05 Fisons Plc Inhalation device
DE4027391A1 (de) * 1990-08-30 1992-03-12 Boehringer Ingelheim Kg Treibgasfreies inhalationsgeraet
US5507281A (en) * 1990-08-30 1996-04-16 Boehringer Ingelheim Kg Device for initiating a mechanical switching operation in synchronism with the breathing
EP0503031B1 (en) 1990-09-26 1998-04-01 Pharmachemie B.V. Inhaler devices provided with a reservoir for several doses of medium for inhaling, transporting device, whirl chamber
GB9026025D0 (en) * 1990-11-29 1991-01-16 Boehringer Ingelheim Kg Inhalation device
US5290539A (en) * 1990-12-21 1994-03-01 Minnesota Mining And Manufacturing Company Device for delivering an aerosol
DE4108393A1 (de) * 1991-03-15 1992-09-17 Boehringer Ingelheim Kg Neue ester bi- und tricyclischer aminoalkohole, ihre herstellung und ihre verwendung in arzneimitteln
AU650953B2 (en) * 1991-03-21 1994-07-07 Novartis Ag Inhaler
GB9202519D0 (en) * 1992-02-06 1992-03-25 Glaxo Group Ltd Medicaments
DE4239402A1 (de) * 1992-11-24 1994-05-26 Bayer Ag Pulverinhalator
DE69324161T2 (de) * 1992-12-09 1999-10-28 Boehringer Ingelheim Pharmaceuticals Inc., Ridgefield Stabilisierte medizinische aerosollösungen
RU2111020C1 (ru) 1992-12-18 1998-05-20 Шеринг Корпорейшн Ингалятор для порошковых лекарств
GB9412434D0 (en) * 1994-06-21 1994-08-10 Inmos Ltd Computer instruction compression
CZ296209B6 (cs) 1995-04-14 2006-02-15 Glaxo Wellcome Inc. Inhalátor a inhalacní systém
BR9608997A (pt) 1995-06-21 1999-06-29 Asta Medica Ag Cartucho para pó farmacêutico com dispositivo de medição integrado e intalador para medicamentos em pó
DE19528145A1 (de) * 1995-08-01 1997-02-06 Boehringer Ingelheim Kg Neue Arzneimittel und ihre Verwendung
DE19536902A1 (de) * 1995-10-04 1997-04-10 Boehringer Ingelheim Int Vorrichtung zur Hochdruckerzeugung in einem Fluid in Miniaturausführung
US5846983A (en) * 1996-02-09 1998-12-08 Mayo Foundation For Medical Education And Research Colonic delivery of nicotine to treat inflammatory bowel disease
US6150415A (en) * 1996-08-13 2000-11-21 The Regents Of The University Of California Epoxide hydrolase complexes and methods therewith
US5885834A (en) * 1996-09-30 1999-03-23 Epstein; Paul M. Antisense oligodeoxynucleotide against phosphodiesterase
US6495167B2 (en) * 1997-03-20 2002-12-17 Schering Corporation Preparation of powder agglomerates
ITMI981671A1 (it) * 1998-07-21 2000-01-21 Zambon Spa Derivati ftalazinici inibitori della fosfodisterasi 4
CA2338680C (en) * 1998-08-04 2008-10-14 Jago Research Ag Medicinal aerosol formulations
DE19847968A1 (de) * 1998-10-17 2000-04-20 Boehringer Ingelheim Pharma Verschlußkappe und Behälter als Zweikammer-Kartusche für Vernebler zur Erzeugung von Aerosolen
GB9902689D0 (en) * 1999-02-08 1999-03-31 Novartis Ag Organic compounds
DE19921693A1 (de) * 1999-05-12 2000-11-16 Boehringer Ingelheim Pharma Neuartige Arzneimittelkompositionen auf der Basis von anticholinergisch wirksamen Verbindungen und ß-Mimetika
GB9913083D0 (en) * 1999-06-04 1999-08-04 Novartis Ag Organic compounds
ES2165768B1 (es) * 1999-07-14 2003-04-01 Almirall Prodesfarma Sa Nuevos derivados de quinuclidina y composiciones farmaceuticas que los contienen.
US7214687B2 (en) * 1999-07-14 2007-05-08 Almirall Ag Quinuclidine derivatives and medicinal compositions containing the same
GB9928311D0 (en) * 1999-11-30 2000-01-26 Novartis Ag Organic compounds
US6410563B1 (en) * 1999-12-22 2002-06-25 Merck Frosst Canada & Co. Substituted 8-arylquinoline phosphodiesterase-4 inhibitors
FR2803378B1 (fr) * 1999-12-29 2004-03-19 Valeo Climatisation Echangeur de chaleur a tubes a plusieurs canaux, en particulier pour vehicule automobile
AU2710301A (en) * 2000-01-28 2001-08-07 Asahi Kasei Kabushiki Kaisha Novel remedies with the use of beta3 agonist
DE60125026T2 (de) * 2000-03-23 2007-06-28 Takeda Pharmaceutical Co. Ltd. Fluorisochinolinderivate, verfahren zu ihrer herstellung und ihre anwendung
GB0008485D0 (en) * 2000-04-07 2000-05-24 Glaxo Group Ltd Pharmaceutical compositions
GB0009605D0 (en) 2000-04-18 2000-06-07 Glaxo Group Ltd Medicaments
GB0009583D0 (en) 2000-04-18 2000-06-07 Glaxo Group Ltd Respiratory formulations
GB0009592D0 (en) 2000-04-18 2000-06-07 Glaxo Group Ltd Respiratory combinations
GB0009606D0 (en) 2000-04-18 2000-06-07 Glaxo Group Ltd Therapeutic combinations
MXPA02011414A (es) * 2000-05-22 2003-06-06 Chiesi Farma Spa Formulaciones farmaceuticas en solucion estable para inhaladores presurizados con medicion de dosis.
US20020052312A1 (en) * 2000-05-30 2002-05-02 Reiss Theodore F. Combination therapy of chronic obstructive pulmonary disease using muscarinic receptor antagonists
AU2001289652A1 (en) * 2000-06-28 2002-01-08 Aventis Pharma S.A. Compositions and methods for regulating the cell cycle using a ki gene or polypeptide
US6706726B2 (en) * 2000-10-14 2004-03-16 Boehringer Ingelheim Pharma Gmbh & Co. Kg Anticholinergics which may be used as medicaments as well as processes for preparing them
US6852728B2 (en) * 2000-10-14 2005-02-08 Boehringer Ingelheim Pharma Gmbh & Co. Kg Anticholinergics, processes for preparing them, and pharmaceutical compositions containing them
US6608054B2 (en) * 2001-03-20 2003-08-19 Boehringer Ingelheim Pharma Kg Pharmaceutical compositions based on anticholinergics and endothelin antagonists
AU2002210575A1 (en) 2000-10-31 2002-05-15 Boehringer Ingelheim Pharma Gmbh & Co. Kg Novel medicament compositions based on anticholinergics and corticosteroids
US7776315B2 (en) * 2000-10-31 2010-08-17 Boehringer Ingelheim Pharma Gmbh & Co. Kg Pharmaceutical compositions based on anticholinergics and additional active ingredients
DE10062712A1 (de) * 2000-12-15 2002-06-20 Boehringer Ingelheim Pharma Neue Arzneimittelkompositionen auf der Basis von Anticholinergika und Corticosteroiden
US20020151541A1 (en) * 2000-10-31 2002-10-17 Michel Pairet Pharmaceutical compositions containing tiotropium salts and antihistamines and their use
US20030158196A1 (en) * 2002-02-16 2003-08-21 Boehringer Ingelheim Pharma Gmbh Co. Kg Pharmaceutical compositions based on anticholinergics and EGFR kinase inhibitors
US20020183292A1 (en) * 2000-10-31 2002-12-05 Michel Pairet Pharmaceutical compositions based on anticholinergics and corticosteroids
US20020137764A1 (en) * 2000-10-31 2002-09-26 Karin Drechsel Inhalable formulation of a solution containing a tiotropium salt
US20020193393A1 (en) * 2001-03-07 2002-12-19 Michel Pairet Pharmaceutical compositions based on anticholinergics and PDE-IV inhibitors
US6620438B2 (en) * 2001-03-08 2003-09-16 Boehringer Ingelheim Pharma Kg Pharmaceutical compositions based on anticholinergics and NK1-receptor antagonists
US20020122773A1 (en) * 2000-12-20 2002-09-05 Michel Pairet Pharmaceutical compositions based on anticholinergics and dopamine agonists
US20020193392A1 (en) * 2000-11-13 2002-12-19 Christel Schmelzer Pharmaceutical compositions based on tiotropium salts of salts of salmeterol
DE10056104A1 (de) * 2000-11-13 2002-05-23 Boehringer Ingelheim Pharma Neue Arzneimittelkompositionen auf der Basis von Tiotropiumsalzen und Salzen des Salmeterols
UA75626C2 (en) * 2000-12-28 2006-05-15 Almirall Prodesfarma Ag Quinuclidine derivatives and medicinal compositions containing the same
US20020189610A1 (en) * 2001-02-01 2002-12-19 Karl-Heinz Bozung Pharmaceutical compositions containing an ipratropium salt and a betamimetic
US20020179087A1 (en) * 2001-02-01 2002-12-05 Karl-Heinz Bozung Pharmaceutical compositions containing an oxitropium salt and a betamimetic
US6667344B2 (en) * 2001-04-17 2003-12-23 Dey, L.P. Bronchodilating compositions and methods
US20030216329A1 (en) * 2001-04-24 2003-11-20 Robinson Cynthia B. Composition, formulations & kit for treatment of respiratory & lung disease with dehydroepiandrosterone(s) steroid & an anti-muscarinic agent(s)
AU2002314102A1 (en) * 2001-05-25 2002-12-09 Boehringer Ingelheim Pharma Gmbh & Co. Kg Combination of a pde4 inhibitor and tiotropium or derivate thereof for treating obstructive airways
GB0115181D0 (en) * 2001-06-20 2001-08-15 Glaxo Group Ltd Novel use
DE10130371A1 (de) * 2001-06-23 2003-01-02 Boehringer Ingelheim Pharma Neue Arzneimittelkompositionen auf der Basis von Anticholinergika, Corticosteroiden und Betamimetika
US20030018019A1 (en) 2001-06-23 2003-01-23 Boehringer Ingelheim Pharma Kg Pharmaceutical compositions based on anticholinergics, corticosteroids and betamimetics
US6919325B2 (en) * 2001-09-14 2005-07-19 Boehringer Ingelheim Pharma Kg Pharmaceutical compositions containing tiotropium salts and low-solubility salmeterol salts
US6974803B2 (en) * 2001-12-06 2005-12-13 Pfizer Inc Pharmaceutical combination
US6790856B2 (en) * 2002-01-31 2004-09-14 Boehringer Ingelheim Pharma Kg Fluorenecarboxylic acid esters, process for the manufacture thereof, and use thereof as medicaments
GB0202635D0 (en) * 2002-02-05 2002-03-20 Glaxo Wellcome Mfg Pte Ltd Formulation containing novel anti-inflammatory androstane derivative
US6756508B2 (en) * 2002-03-04 2004-06-29 Boehringer Ingelheim Pharma Gmbh & Co. Kg Cinnamic acid salts, processes for their preparation, and their use as medicaments
US7094788B2 (en) * 2002-04-13 2006-08-22 Boehringer Ingelheim Pharma Gmbh & Co. Kg Esters of hydroxyl-substituted nitrogen heterocycles, processes for the preparation thereof as well as the use thereof as pharmaceutical compositions
ES2206021B1 (es) * 2002-04-16 2005-08-01 Almirall Prodesfarma, S.A. Nuevos derivados de pirrolidinio.
ES2195785B1 (es) 2002-05-16 2005-03-16 Almirall Prodesfarma, S.A. Nuevos derivados de piridazin-3(2h)-ona.
NZ536555A (en) * 2002-05-17 2007-03-30 Novartis Ag Pharmaceutical composition comprising a renin inhibitor, a calcium channel blocker and a diuretic
JP2006504666A (ja) * 2002-06-12 2006-02-09 エピジェネシス ファーマシューティカルズ リミティド ライアビリティー カンパニー デヒドロエピアンドロステロン・ステロイド及び抗ムスカリン薬で呼吸器及び肺の疾患を治療するための組成物、配合物及びキット
EA200500173A1 (ru) * 2002-07-08 2005-08-25 Рэнбакси Лабораториз Лимитед Производные 3,6-дизамещенного азабицикло[3.1.0]гексана в качестве антагонистов мускариновых рецепторов
US20040058950A1 (en) * 2002-07-09 2004-03-25 Boehringer Ingelheim Pharma Gmbh & Co. Kg Pharmaceutical compositions based on anticholinergics and PDE-IV inhibitors
WO2004039968A1 (ja) * 2002-10-30 2004-05-13 Japan Science And Technology Agency 骨髄由来の不死化樹状細胞株
ES2211315B1 (es) 2002-11-12 2005-10-16 Almirall Prodesfarma, S.A. Nuevos compuestos triciclicos.
AU2003289898A1 (en) * 2002-11-27 2004-06-18 Altana Pharma Ag Pde4 and pde3/4 inhibitors for use in the treatment of cachexia
ES2211344B1 (es) 2002-12-26 2005-10-01 Almirall Prodesfarma, S.A. Nuevos derivados de piridazin-3(2h)-ona.
PE20040950A1 (es) * 2003-02-14 2005-01-01 Theravance Inc DERIVADOS DE BIFENILO COMO AGONISTAS DE LOS RECEPTORES ADRENERGICOS ß2 Y COMO ANTAGONISTAS DE LOS RECEPTORES MUSCARINICOS
DE10307759B3 (de) * 2003-02-19 2004-11-18 Schering Ag Trimere makrocyclisch substituierte Benzolderivate, deren Herstellung und Verwendung als Kontrastmittel sowie diese enthaltende pharmazeutische Mittel
US20040184995A1 (en) * 2003-03-17 2004-09-23 Yamanouchi Pharmaceutical Co., Ltd. Novel dry powder inhalation for lung-delivery and manufacturing method thereof
US20060147382A1 (en) * 2003-03-28 2006-07-06 Altana Pharma Ag Synergistic combination comprising roflumilast and an anticholinergic agent selected from ipratropium, oxitropium and tiotropium salts for the treatment of respiratory diseases
MXPA05010161A (es) * 2003-03-28 2005-11-16 Altana Pharma Ag Combinacion sinergistica que comprende roflumilast y un agente anticolinergico seleccionado a partir de sales de ipratropio, oxitropio y tiotropio para el tratamiento de enfermedades respiratorias.
CN1829534A (zh) † 2003-07-29 2006-09-06 贝林格尔.英格海姆国际有限公司 包括β模拟物和抗胆碱能药的吸入药剂
US20050026886A1 (en) * 2003-07-29 2005-02-03 Boehringer Ingelheim International Gmbh Medicaments for inhalation comprising an anticholinergic and a PDE IV inhibitor
US20050026887A1 (en) * 2003-07-29 2005-02-03 Boehringer Ingelheim International Gmbh Medicaments for inhalation comprising an anticholinergic and a steroid
US20050026948A1 (en) * 2003-07-29 2005-02-03 Boehringer Ingelheim International Gmbh Medicaments for inhalation comprising an anticholinergic and a betamimetic
CA2534120C (en) * 2003-07-31 2012-09-11 Boehringer Ingelheim International Gmbh Medicaments for inhalation comprising anticholinergics and a betamimetic
US20050025718A1 (en) * 2003-07-31 2005-02-03 Boehringer Ingelheim International Gmbh Medicaments for inhalation comprising an anticholinergic and a betamimetic
DE10347994A1 (de) * 2003-10-15 2005-06-16 Pari GmbH Spezialisten für effektive Inhalation Wässrige Aerosol-Zubereitung
ES2232306B1 (es) 2003-11-10 2006-08-01 Almirall Prodesfarma, S.A. Nuevos derivados de piridazin-3(2h)-ona.
PL1718336T3 (pl) * 2004-02-06 2008-11-28 Meda Pharma Gmbh & Co Kg Nowe połączenie środków antycholinergicznych i beta-mimetyków do leczenia chorób układu oddechowego
CN101518532A (zh) * 2004-02-06 2009-09-02 Meda制药有限及两合公司 用于呼吸道疾病治疗的抗胆碱能药和4型磷酸二酯酶抑制剂的组合
SI1713473T1 (sl) * 2004-02-06 2013-06-28 Meda Pharma Gmbh & Co. Kg Kombinacija antiholinergikov in glukokortikoidov za dolgotranjno zdravljenje astme in KOPB
US7375935B2 (en) * 2004-04-12 2008-05-20 Leviton Manufacturing Co., Inc. Ground fault circuit interrupter with enhanced radio frequency interference suppression
ES2257152B1 (es) * 2004-05-31 2007-07-01 Laboratorios Almirall S.A. Combinaciones que comprenden agentes antimuscarinicos y agonistas beta-adrenergicos.
US20060189551A1 (en) * 2004-10-04 2006-08-24 Duke University Combination therapies for fungal pathogens

Also Published As

Publication number Publication date
AR049066A1 (es) 2006-06-21
US20070232637A1 (en) 2007-10-04
JP5133054B2 (ja) 2013-01-30
CN102085373A (zh) 2011-06-08
US20100048615A1 (en) 2010-02-25
ES2318498T3 (es) 2009-05-01
EP2774623B1 (en) 2015-04-08
ECSP067038A (es) 2006-12-29
GB0526502D0 (en) 2006-02-08
US20110021477A1 (en) 2011-01-27
SI2292267T1 (sl) 2014-11-28
US20090099148A1 (en) 2009-04-16
NZ551668A (en) 2010-06-25
RS50787B (sr) 2010-08-31
NO20065483L (no) 2006-12-22
ZA200609990B (en) 2007-12-27
JP2008500990A (ja) 2008-01-17
BRPI0511662B8 (pt) 2021-05-25
WO2005115466A8 (en) 2007-01-04
WO2005115466A1 (en) 2005-12-08
IL179684A0 (en) 2007-05-15
EP2292267A3 (en) 2011-06-15
HRP20090215T4 (hr) 2013-12-20
RU2006147268A (ru) 2008-07-20
SI1763368T1 (sl) 2009-08-31
US20100056486A1 (en) 2010-03-04
US20120088743A1 (en) 2012-04-12
ATE417627T1 (de) 2009-01-15
AU2005247108B2 (en) 2008-09-11
HRP20100489T1 (hr) 2010-10-31
RU2006147250A (ru) 2008-07-20
RU2465902C2 (ru) 2012-11-10
BRPI0511660A (pt) 2008-01-02
JP2012184272A (ja) 2012-09-27
MY142095A (en) 2010-09-15
BRPI0511669A (pt) 2008-01-02
KR20130027586A (ko) 2013-03-15
ECSP067037A (es) 2006-12-29
EP2002843A2 (en) 2008-12-17
DE602005011803D1 (de) 2009-01-29
US20090111785A1 (en) 2009-04-30
ZA200609987B (en) 2007-12-27
US20080146603A1 (en) 2008-06-19
CN1960759B (zh) 2011-07-13
DK1891973T3 (da) 2010-10-18
US20150202213A1 (en) 2015-07-23
US20130310354A1 (en) 2013-11-21
PL1763368T3 (pl) 2009-08-31
DK1763368T3 (da) 2009-05-04
JP5107701B2 (ja) 2012-12-26
HUP0600139A3 (en) 2010-12-28
CY1110798T1 (el) 2015-06-10
DK1763369T3 (da) 2009-03-16
NZ544539A (en) 2007-09-28
CA2568566C (en) 2012-12-18
RU2404771C2 (ru) 2010-11-27
EP2002844B1 (en) 2010-12-29
CN1960761A (zh) 2007-05-09
EP2319538A2 (en) 2011-05-11
ES2257152A1 (es) 2006-07-16
CA2569077C (en) 2012-12-18
JP2008500989A (ja) 2008-01-17
BRPI0511656A (pt) 2008-01-02
ME01670B (me) 2010-06-30
US20110021478A1 (en) 2011-01-27
CY1115669T1 (el) 2017-01-25
US20170049756A1 (en) 2017-02-23
IL179687A (en) 2011-11-30
FR15C0017I2 (fr) 2015-11-13
HK1198120A1 (en) 2015-03-13
DK2292267T3 (da) 2014-09-15
EP1763369B1 (en) 2008-12-17
US20130252928A1 (en) 2013-09-26
CN102755321A (zh) 2012-10-31
IL179687A0 (en) 2007-05-15
SI1763369T1 (sl) 2009-06-30
JP2006527183A (ja) 2006-11-30
ATE474600T1 (de) 2010-08-15
PL1765404T3 (pl) 2009-06-30
ECSP067036A (es) 2006-12-29
SI1763368T2 (sl) 2013-12-31
EP2774622B1 (en) 2015-03-11
NZ551667A (en) 2010-07-30
NO2015007I2 (no) 2015-12-21
JP5049120B2 (ja) 2012-10-17
MXPA06004124A (es) 2006-06-27
US20140148420A1 (en) 2014-05-29
UA86976C2 (ru) 2009-06-10
DK1763368T4 (da) 2013-11-04
FR2870744A1 (fr) 2005-12-02
CY2015006I1 (el) 2016-06-22
JP4966192B2 (ja) 2012-07-04
FR2870744B1 (fr) 2006-12-08
US20100048616A1 (en) 2010-02-25
GR1006045B (el) 2008-09-08
PE20081649A1 (es) 2008-11-28
CN102755321B (zh) 2015-07-15
US20120040943A1 (en) 2012-02-16
JP2008500986A (ja) 2008-01-17
RS51386B (en) 2011-02-28
US20080045565A1 (en) 2008-02-21
AU2005247108A1 (en) 2005-12-08
BRPI0511662B1 (pt) 2019-02-19
EP2138188A1 (en) 2009-12-30
RS50787B2 (sr) 2018-02-28
EP1763368B1 (en) 2009-03-11
ZA200600261B (en) 2007-04-25
CN1972716A (zh) 2007-05-30
US20090093503A1 (en) 2009-04-09
ME01680B (me) 2010-08-31
PL1763369T3 (pl) 2009-06-30
NO20065482L (no) 2006-12-22
CL2011000607A1 (es) 2011-08-19
US20120309726A1 (en) 2012-12-06
LU91214B1 (fr) 2006-01-26
RS50717B (sr) 2010-06-30
CY1109139T1 (el) 2014-07-02
AU2005247103A1 (en) 2005-12-08
PT2292267E (pt) 2014-10-15
EP2774623A1 (en) 2014-09-10
NL1029151A1 (nl) 2005-12-05
PT1763369E (pt) 2009-02-26
CY1108885T1 (el) 2014-07-02
CH696962A5 (fr) 2008-02-29
PT1763368E (pt) 2009-05-14
JP4928258B2 (ja) 2012-05-09
CA2568566A1 (en) 2005-12-08
RU2385721C2 (ru) 2010-04-10
EP2210613A1 (en) 2010-07-28
PE20060292A1 (es) 2006-04-14
EP2002844A2 (en) 2008-12-17
ITMI20051021A1 (it) 2005-12-01
US20150306079A1 (en) 2015-10-29
UA89181C2 (ru) 2010-01-11
US20120071452A1 (en) 2012-03-22
US20050267135A1 (en) 2005-12-01
MXPA06013847A (es) 2007-03-01
EP1761280A1 (en) 2007-03-14
JP5032984B2 (ja) 2012-09-26
KR20070018105A (ko) 2007-02-13
NL1029151C2 (nl) 2006-06-22
WO2005115467A1 (en) 2005-12-08
UA89184C2 (ru) 2010-01-11
US20120309727A1 (en) 2012-12-06
JP2008500988A (ja) 2008-01-17
AU2005247107A1 (en) 2005-12-08
CY1108902T1 (el) 2014-07-02
PL1763368T5 (pl) 2014-01-31
JP5538485B2 (ja) 2014-07-02
ES2322280T5 (es) 2013-12-03
TWI404530B (zh) 2013-08-11
CY2015006I2 (el) 2016-06-22
HUS1500011I1 (hu) 2018-09-28
HK1090306A1 (en) 2006-12-22
CN101018566A (zh) 2007-08-15
US20200009117A1 (en) 2020-01-09
PE20081650A1 (es) 2008-12-06
ES2322280T3 (es) 2009-06-18
US20130035319A1 (en) 2013-02-07
RU2373935C2 (ru) 2009-11-27
ME02134B (me) 2015-02-27
US20050288266A1 (en) 2005-12-29
EP1763369A1 (en) 2007-03-21
SI21784A (sl) 2005-12-31
ECSP067034A (es) 2006-12-29
NO334337B1 (no) 2014-02-10
CA2533061A1 (en) 2005-12-08
ES2293849A1 (es) 2008-03-16
US20080051378A1 (en) 2008-02-28
DE602005022497D1 (de) 2010-09-02
US20070167489A1 (en) 2007-07-19
US20060189651A1 (en) 2006-08-24
AU2005247107B2 (en) 2010-10-28
US20180200234A1 (en) 2018-07-19
ME02779B (me) 2010-06-30
NL300720I1 (enrdf_load_stackoverflow) 2016-01-07
JP2008500987A (ja) 2008-01-17
BRPI0511662A (pt) 2008-01-02
HRP20090107T3 (en) 2009-03-31
GB2419819A (en) 2006-05-10
HRP20140864T1 (hr) 2014-12-05
UA89183C2 (ru) 2010-01-11
CN1960759A (zh) 2007-05-09
EP1763368B2 (en) 2013-08-21
US20150080359A1 (en) 2015-03-19
NO20065477L (no) 2006-12-22
EP2292267A2 (en) 2011-03-09
IL179689A (en) 2012-02-29
ZA200609985B (en) 2008-09-25
BRPI0511667A (pt) 2008-01-02
UY28933A1 (es) 2005-08-31
GR20050100269A (el) 2005-12-31
SI1891973T1 (sl) 2010-11-30
PL2292267T3 (pl) 2015-03-31
US20060205702A1 (en) 2006-09-14
TW200608971A (en) 2006-03-16
BRPI0511666A (pt) 2008-01-02
US20060154934A1 (en) 2006-07-13
NO338621B1 (no) 2016-09-19
DE602005013220D1 (de) 2009-04-23
MC200083A1 (fr) 2005-12-07
RS53529B1 (en) 2015-02-27
CA2569077A1 (en) 2005-12-08
IL179684A (en) 2011-11-30
ES2257152B1 (es) 2007-07-01
EP1765404A1 (en) 2007-03-28
US20110021476A1 (en) 2011-01-27
EP2292267B1 (en) 2014-07-23
US20140094442A1 (en) 2014-04-03
US20120302532A1 (en) 2012-11-29
EP1763368A1 (en) 2007-03-21
NL300720I2 (enrdf_load_stackoverflow) 2016-01-07
NO2015007I1 (no) 2015-03-09
US20140296197A1 (en) 2014-10-02
EP2319538A3 (en) 2011-06-15
HK1095757A1 (en) 2007-05-18
HK1125573A1 (en) 2009-08-14
RU2010129940A (ru) 2012-01-27
UA89182C2 (ru) 2010-01-11
EP2002845A3 (en) 2009-02-25
EP2002845A2 (en) 2008-12-17
PL379660A1 (pl) 2006-11-13
NO20065479L (no) 2006-12-22
US20090176751A1 (en) 2009-07-09
ZA200609989B (en) 2007-11-28
DK1765404T3 (da) 2009-03-16
PT1891973E (pt) 2010-09-27
WO2005115462A1 (en) 2005-12-08
RU2404771C3 (ru) 2018-03-12
ES2348558T3 (es) 2010-12-09
AU2005247103B2 (en) 2010-10-28
EP2002844A3 (en) 2009-03-04
EP2002843A3 (en) 2009-04-08
PL1891973T3 (pl) 2010-11-30
GB2419819B (en) 2007-02-21
EP1891973B1 (en) 2010-07-21
JP2012012407A (ja) 2012-01-19
NO20065476L (no) 2006-12-28
MXPA06013848A (es) 2007-03-01
HRP20090215T1 (hr) 2009-05-31
ES2348680T3 (es) 2010-12-10
ZA200609986B (en) 2007-11-28
US20160038470A1 (en) 2016-02-11
IL179689A0 (en) 2007-05-15
US20050267078A1 (en) 2005-12-01
CA2533061C (en) 2008-07-08
ECSP067033A (es) 2006-12-29
RU2006142331A (ru) 2008-06-20
KR101256417B1 (ko) 2013-04-22
ATE424847T1 (de) 2009-03-15
US20120059031A1 (en) 2012-03-08
CY1109938T1 (el) 2014-09-10
HUP0600139A2 (en) 2007-06-28
UA89185C2 (ru) 2010-01-11
BE1016608A5 (fr) 2007-02-06
KR20070024556A (ko) 2007-03-02
LTC1763368I2 (lt) 2016-12-27
ES2505329T3 (es) 2014-10-09
CN1960760A (zh) 2007-05-09
KR101174677B1 (ko) 2012-08-17
EP2774622A1 (en) 2014-09-10
IE20050366A1 (en) 2005-11-30
CN1960762A (zh) 2007-05-09
ECSP067035A (es) 2006-12-29
ES2293849B2 (es) 2009-04-16
EP1765404B1 (en) 2008-12-31
EP1891973A1 (en) 2008-02-27
NO20065478L (no) 2006-12-28

Similar Documents

Publication Publication Date Title
BE2024C508I2 (enrdf_load_stackoverflow)
BE2022C549I2 (enrdf_load_stackoverflow)
BE2023C542I2 (enrdf_load_stackoverflow)
BE2021C001I2 (enrdf_load_stackoverflow)
BE2020C513I2 (enrdf_load_stackoverflow)
BE2020C517I2 (enrdf_load_stackoverflow)
BE2019C540I2 (enrdf_load_stackoverflow)
BE2019C523I2 (enrdf_load_stackoverflow)
BE2019C506I2 (enrdf_load_stackoverflow)
BE2019C548I2 (enrdf_load_stackoverflow)
BE2018C045I2 (enrdf_load_stackoverflow)
BE2020C525I2 (enrdf_load_stackoverflow)
BE2017C063I2 (enrdf_load_stackoverflow)
BE2017C027I2 (enrdf_load_stackoverflow)
BE2017C023I2 (enrdf_load_stackoverflow)
BE2017C002I2 (enrdf_load_stackoverflow)
BE2016C067I2 (enrdf_load_stackoverflow)
BE2016C014I2 (enrdf_load_stackoverflow)
BE2015C041I2 (enrdf_load_stackoverflow)
BE2015C038I2 (enrdf_load_stackoverflow)
BE2015C066I2 (enrdf_load_stackoverflow)
BE2019C535I2 (enrdf_load_stackoverflow)
JP2005050342A5 (enrdf_load_stackoverflow)
BE2015C065I2 (enrdf_load_stackoverflow)
BE2016C035I2 (enrdf_load_stackoverflow)